SecBot SecBot

ORIC

Oric Pharmaceuticals, Inc.
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001796280 Biotech & Drug Discovery
$7.52 −0.34 (−4.33%)
Nov 16 4:00 PM ET · prev $7.86
Market cap
$881.0M
Small cap
Consensus
Buy
91% Buy or better · 22 analysts
Median target
$23.50
+213% · range $14.00–27.00
1 year
−37.6%
from $12.06 · Nov 17
30 days
−40.9%
from $12.72
52-week range
$7.47–14.65
−49% from high · low Apr 1
Avg volume 20D
1.98M
Oct 26 spike 6.94M
Short interest
10.73M
≈10.3% of shares · −30.4%
Days to cover
4.8
at average volume
Insider net
−$2.4M
0 buyers · 2 sellers · 12 mo
New fund stakes
0
Q3 2026 13F · 0 exits
Filing reports
10
analyzed by SecBot
SecBot read BULLISH 7 reports · 90 days
Balance 0 bearish · 2 bullish · 1 mixed · 4 neutral oldest → newest, height = score
Avg score ·High conf. 3/7

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersBEARISH

    2 insiders sold $2.4M.

  • InstitutionsBULLISH

    Q3 2026: 23 added (0 new), 11 trimmed or exited.

  • AnalystsBULLISH

    20 of 22 rate it Buy or better. Every target is above the price.

  • Short sellersCOVERING

    Short interest −30.4% to 10.73M shares. 4.8 days to cover, ≈10.3% of shares.

  • TrendDOWNTREND

    34% below its 50-day average.

Who's buying

13F· Q3 2026
0
new positions
0
exits
FundMoveSharesValue
Qube Research & Technologies LtdDOUBLED1,642,227$22.1M
Candriam S.C.A.TRIM788,125$10.7M
ROYCE & ASSOCIATES LPTRIM534,953$7.2M
HRT FINANCIAL LPDOUBLED513,589$6.9M
Nuveen, LLCDOUBLED483,338$6.5M
CITIGROUP INCTRIM185,763$2.5M
Jump Financial, LLCADD182,988$2.5M
Russell Investments Group, Ltd.ADD151,473$2.0M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

22 analysts
Buy 91% rate it Buy or better
Strong Buy10Buy10Hold2Sell0Strong Sell0
12-month targets · 14 analysts

Price is below the lowest target. Median implies +213%.Targets as of Nov 17, 2026.

Recent actions
DateFirmActionRating
Oct 28, 2026BTIG
REITERATE
REITERATEBuy
Oct 27, 2026Wedbush
MAINTAIN
MAINTAINOutperform
Oct 26, 2026Stifel
MAINTAIN
MAINTAINBuy
Oct 14, 2026JP Morgan
MAINTAIN
MAINTAINOverweight
Oct 5, 2026Leerink Partners
INITIATE
INITIATEOutperform
Sep 23, 2026BTIG
INITIATE
INITIATEBuy

Insider ledger

Form 4
$0
bought · 0 insiders
$2.4M
sold · 2 insiders
DateInsiderTypeValue
Oct 20, 2026
Piscitelli Dominic
Chief Financial Officer
Oct 20, 2026
EXERCISE$61.0K
Oct 20, 2026
Piscitelli Dominic
Chief Financial Officer
Oct 20, 2026
SELL$189.4K
Oct 1, 2026
Heyman Richard A.
Director
Oct 1, 2026
SELL$41.3K
Oct 1, 2026
Heyman Richard A.
Director
Oct 1, 2026
EXERCISE$5.6K
Oct 1, 2026
Heyman Richard A.
Director
Oct 1, 2026
SELL$45.2K
Sep 28, 2026
Piscitelli Dominic
Chief Financial Officer
Sep 28, 2026
EXERCISE$58.4K
Sep 28, 2026
Piscitelli Dominic
Chief Financial Officer
Sep 28, 2026
SELL$181.3K
Sep 24, 2026
Piscitelli Dominic
Chief Financial Officer
Sep 24, 2026
EXERCISE$2.6K

Earnings setup

Estimates

Revision history: 🔒 Fresh data, subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data, subscribers only
Next Q🔒 Fresh data, subscribers only
Current FY🔒 Fresh data, subscribers only
Next FY🔒 Fresh data, subscribers only

Short side

FINRA· Oct 30, 2026
10,730,120
shares short
-30.4%
vs prior settlement
4.8
days to cover
≈10.3%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 16, 2026 SEC
🔒 Fresh report (last 24h), subscribers only
Nov 16, 2026 Earnings
🔒 Fresh data, subscribers only
Nov 16, 2026 SEC
🔒 Fresh report (last 24h), subscribers only
Nov 16, 2026 SEC
🔒 Fresh report (last 24h), subscribers only
Oct 20, 2026 Insider
Piscitelli Dominic acquired via exercise 14,000 shares
Chief Financial Officer @ $4.36 ($61.0K)
Oct 20, 2026 Insider
Piscitelli Dominic sold 14,000 shares
Chief Financial Officer @ $13.53 ($189.4K)
Oct 5, 2026 Press
ORIC Pharmaceuticals announced a partnership with Cancer Research UK to fully fund and execute CTA-enabling studies…
Impact 6/10
Oct 1, 2026 Insider
Heyman Richard A. sold 3,200 shares
Director @ $12.91 ($41.3K)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
2 drugs tracked · Drug pipeline →
Recent
Nov 16, 2026
Earnings
🔒 Fresh data, subscribers only
Nov 16, 2026
Earnings result
🔒 Fresh data, subscribers only
Nov 12, 2026
Earnings date
ORIC Q3 2026 Earnings Scheduled · 2026-11-12
Nov 9, 2026
Earnings date
ORIC Q3 2026 Earnings Scheduled · 2026-11-09
Nov 6, 2026
Press release
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Nov. 06, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology…

SecBot reports

10 filings · 2 press releases · 1 bullish · 0 bearish · 2 mixed · 7 neutral
All ORIC filing & press-release reports (12)